SCHEMBL2174136

SCHEMBL2174136

O=C(NO)[C@H]1C[C@H](N(C(=O)O)C2CC2c2ccccc2)CC[C@@H]1C(=O)N1CCN(c2ccccc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM10 O14672 15/20 0.59
MMP2 P08253 14/20 0.59
ERBB2 P04626 14/20 0.59
SIGMAR1 Q99720 1/20 0.55
MMP9 P14780 7/20 0.54
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MMP3 P08254 1/20 0.44
CTSB P07858 2/20 0.43
CTSS P25774 2/20 0.43
CTSK P43235 2/20 0.43
MMP8 P22894 1/20 0.43
MMP12 P39900 1/20 0.43
ADAM17 P78536 1/20 0.43
KDM1A O60341 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16393952 0.89 ADAM10 (0.67) ADAM10MMP2ERBB2SIGMAR1MMP9
SCHEMBL2176151 0.86 ADAM10 (0.64) ADAM10MMP2ERBB2SIGMAR1MMP9
SCHEMBL2174078 0.86 ADAM10 (0.61) ADAM10MMP2ERBB2SIGMAR1MMP9
SCHEMBL2176356 0.85 ADAM10 (0.62) ADAM10MMP2ERBB2SIGMAR1MMP9
SCHEMBL2172008 0.83 ADAM10 (0.63) ADAM10MMP2ERBB2MMP9MMP3
SCHEMBL2176866 0.83 ADAM10 (0.60) ADAM10MMP2ERBB2MMP9MMP3
SCHEMBL16393953 0.80 ADAM10 (0.57) ADAM10MMP2ERBB2SIGMAR1MMP9
SCHEMBL2172763 0.77 ADAM10 (0.75) ADAM10MMP2ERBB2SIGMAR1MMP9
SCHEMBL2421532 0.77 ADAM10 (0.64) ADAM10MMP2ERBB2MMP9MMP3
SCHEMBL2174691 0.77 ADAM10 (0.61) ADAM10MMP2ERBB2SIGMAR1MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 US claimed
US-9440958-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2016-09-13 US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 ADAM10 25/4885MMP2 4/4885ERBB2 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.